Tpoxx
STOMP Trial Stomped by DSMB—Tecovirimat Did Not Improve Mpox Resolution or Pain
Tpoxx did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate ...
JANUARY 8, 2025
Although Safe, Tecovirimat Did Not Improve Clade I Mpox Resolution in the DRC
The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I ...
OCTOBER 16, 2024
Tecovirimat is Safe but Did Not Improve Clade I Mpox Resolution in the DRC
The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I ...
SEPTEMBER 9, 2024
Doctor’s Lucky Shot Against Mpox
Data from a retrospective cohort study presented at CROI 2024, in Denver, suggest Tpoxx was effective in helping ...
MAY 10, 2024
Lesions Following TPOXX Mpox Treatment
A small number of patients who were treated for mpox with TPOXX have developed new skin or mucosal lesions ...
JULY 10, 2023
FDA Approves TPOXX for Smallpox Treatment
Although WHO declared smallpox—a contagious and sometimes fatal infectious disease—eradicated in 1980, ...
JULY 20, 2018
FDA Advisory Panel Recommends TPOXX for Smallpox Treatment
Naturally occurring smallpox was eradicated worldwide by 1980, but remaining laboratory samples raise raise ...
MAY 4, 2018
Company Requests Priority Review of Tpoxx NDA for Smallpox
SIGA Technologies submitted a New Drug Application to the FDA for its oral formulation of Tpoxx to treat smallpox. ...
DECEMBER 14, 2017
